Drug assessment at a glance: A26-05[1]

Toripalimab (oesophageal carcinoma)

17 August 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-05. The G-BA decides on the added benefit.

Research question 1 of the benefit assessment

Population	Adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma and tumour cell PD-L1 expression ≥ 1% or a CPS ≥ 10; first-line treatment
Intervention	toripalimab + cisplatin + paclitaxel
Comparator	▪ nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy (for patients with tumour cell PD-L1 expression ≥ 1%) or ▪ nivolumab in combination with ipilimumab (for patients with tumour cell PD-L1 expression ≥ 1%) or ▪ pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy (for patients with a CPS ≥ 10)
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects – research question 1

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects – research question 1

- No relevant study was identified.

Research question 2 of the benefit assessment

Population	Adults with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma and no tumour cell PD-L1 expression ≥ 1% and no CPS ≥ 10; first-line treatment
Intervention	toripalimab + cisplatin + paclitaxel
Comparator	cisplatin in combination with 5-fluorouracil
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects – research question 2

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects – research question 2

- No relevant study was identified.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Toripalimab (Ösophaguskarzinom); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 31.07.2026]. URL: https://doi.org/10.60584/A26-05.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Toripalimab (Plattenepithelkarzinom des Ösophagus, Erstlinie, Kombination mit Cisplatin und Paclitaxel) [online]. 2026 [Accessed: 31.07.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1303/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-05.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de